Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    DoD CBRN Medical Countermeasure Consortium

    By Global Biodefense StaffNovember 16, 2015
    CBRN Decontamination Tech Evaluations
    Share
    Facebook LinkedIn Reddit Email

    Military program managers briefed biopharmaceutical industry and research organization representatives during a Nov. 2 Industry Day, part of an initiative to establish a unique consortium for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements.

    Lead by the Joint Project Manager for Medical Countermeasure Systems (JPM-MCS), the Consortium OTA (Other Transaction Agreement) business model is a new binding contractual instrument to work with DOD to develop FDA Licensed Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures. The Consortium OTA will have an initial $10 billion ceiling and a 20-year performance period.

    The effort aims to:

    • Form robust long term partnerships and commitments with qualified providers
    • Pursue effective collaborative research with non-traditional technology providers
    • Move away from burdensome and slow RFP process
    • Create a rapid response capability to emergent threats and requirements
    • Deliver enabling technologies that will support the development MCM prototypes
    • Allows rapid screening of protective molecules and constructs for testing
    • Reduce bid & proposal costs with use of white papers before proposal preparation
    • Overcome obstacles of traditional Intellectual property and FAR requirements
    • Provide faster access to partners with promising therapeutic countermeasures
    • Place technically acceptable proposals placed in the “basket” awaiting funding
    • Provide unity of effort among defense organizations from discovery through FDA Approval
    • Centralize business management and subcontract management

    LTC Marla Ferguson, Joint Product Manager for Chemical Defense Pharmaceuticals, briefed attendees on requirements for therapeutics delivered via autoinjector for the treatment of nerve agent casualties and therapeutics; prophylactics for Acute Radiation Syndrome; well characterized animal models CBRN medical countermeasure development; and innovative and emerging technologies to support rapid development and delivery systems.

    Joint Product Manager for BioDefense Therapeutics, LTC Eric G. Midboe described immediate priorities for enabling prototype technologies for therapeutic medical countermeasures targeting viral, bacterial and biological toxin targets of interest to the DOD, including:

    • Bacterial threats (multi-drug resistant)
    • Yersinia pestis
    • Burkholderia pseudomallei
    • Bacillus anthracis
    • Francisella tularensis
    • Brucella spp
    • Burkholderia mallei
    • Filoviridae (Ebolavirus, Marburgvirus)
    • Hantavirus
    • Alphaviruses (WEE, VEE, EEE)
    • Toxin therapeutics – Botulinum Neurotoxin, Ricin, SEB etc.

    According to LTC Midboe, enabling technologies can include animal models of viral, bacterial or biological toxin disease and pathogenesis (multiple routes of exposure), assays, diagnostic technologies or other platform technologies that can be applied to development of approved or licensed MCMs.

    LTC Victor A. Suarez of the Joint Vaccine Acquisition Program (JVAP) discussed expectations of performers and anticipated requirements for development of vaccines providing broad spectrum protection against a range of biological agents and a range of exposure routes.

    JVAP requirements include:

    • Transition of target protective molecules to industry partners for manufacture
    • Vaccine candidate testing in appropriate animal models and Phase 1 Clinical Trials
    • Taking selected vaccines to FDA licensure using animal rule

    The Industry Day also highlighted the Advanced Development & Manufacturing Capability (ADMC), a contract awarded to Nanotherapeutics in 2013.

    Tim Belski, ADMC Joint Product Director, discussed the potential for consortium partners to utilize ADMC capabilities for biologics process development; manufacturing of monoclonal antibodies, vaccines and recombinant proteins; small molecule development; and regulatory and clinical trial support.

    The ADMC provides stable manufacturing facilities for multiple products and teaming capabilities for companies without inherent capabilities or who do not wish to use their own capabilities on DoD products.

    Letters of Intent for the Consortium OTA are due by Nov. 24, 2015. Further details are available via Solicitation Number: W15QKN-16-Z-3188.

    Animal Models Antimicrobials Antitoxins Antivirals Botulinum Neurotoxin Burkholderia Ebola F. tularensis Marburg Ricin Vaccine News Y. pestis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – Nov 15, 2015
    Next Article Impact of Chemical Weapons Convention on U.S. Industry

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Terrorism and the Pandemic: Weaponizing a Public Health Crisis

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.